Article
Immunology
Ning Ma, Huihui Liu, Yang Zhang, Wei Liu, Zeyin Liang, Qian Wang, Yuhua Sun, Lihong Wang, Yuan Li, Hanyun Ren, Yujun Dong
Summary: This study identifies the testis-cancer antigen AKAP4 as a potential target for multiple myeloma (MM) and demonstrates the efficacy of cytotoxic T lymphocytes (CTLs) targeting AKAP4 in lysis of MM cells.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Romika Kumari, Muntasir Mamun Majumder, Juha Lievonen, Raija Silvennoinen, Pekka Anttila, Nina N. Nupponen, Fredrik Lehmann, Caroline A. Heckman
Summary: This study evaluated the biological significance of esterase expression in multiple myeloma (MM) by analyzing gene expression profiling and genomic variants in patients with newly diagnosed MM (NDMM) or relapsed/refractory MM (RRMM). High or low expression of specific esterases in MM, such as UCHL5, SIAE, ESD, PAFAH1B3, PNPLA4, and PON1, were significantly altered as patients progressed from NDMM to RRMM. Certain esterases, like OVCA2, PAFAH1B3, SIAE, USP4, and PCED1B, were identified as poor prognostic markers, suggesting their potential role in myeloma biology.
BRITISH JOURNAL OF CANCER
(2021)
Article
Multidisciplinary Sciences
Toru Masuda, Shojiro Haji, Yasuhiro Nakashima, Mariko Tsuda, Daisaku Kimura, Akiko Takamatsu, Norifusa Iwahashi, Hironobu Umakoshi, Motoaki Shiratsuchi, Chie Kikutake, Mikita Suyama, Yasuyuki Ohkawa, Yoshihiro Ogawa
Summary: In this study, longitudinal single-cell transcriptome sequencing was performed on multiple myeloma (MM) cells from a patient with relapsed MM. The researchers observed dynamic changes in MM cells in response to anti-myeloma drugs and identified a drug-response gene, PELI2. Their integrated strategy provided new insights into the clonal dynamics of MM and identification of drug-response genes.
Editorial Material
Medicine, General & Internal
Sham Mailankody, Ola Landgren
Summary: BCMA has been recognized as a prognostic marker in multiple myeloma for over two decades, and is now a major target for various treatments including CAR T cells, antibody drug conjugates, and bispecific antibodies. The rapid translation from preclinical studies to FDA-approved treatments demonstrates significant success in the field.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Review
Biochemistry & Molecular Biology
Dominika Bebnowska, Rafal Hrynkiewicz, Ewelina Grywalska, Marcin Pasiarski, Barbara Sosnowska-Pasiarska, Iwona Smarz-Widelska, Stanislaw Gozdz, Jacek Rolinski, Paulina Niedzwiedzka-Rystwej
Summary: The article discusses the prognostic value of immune system components in patients with multiple myeloma to aid in the development of new diagnostic and therapeutic directions.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Oncology
Luis V. Valcarcel, Ane Amundarain, Marta Kulis, Stella Charalampopoulou, Ari Melnick, Jesus San Miguel, Jose Martin-Subero, Francisco J. Planes, Xabier Agirre, Felipe Prosper
Summary: This study identified active promoters and alternative active promoters in different B cell subpopulations and MM patient samples, showing specific expression patterns for each subpopulation. The expression from some alternative promoters was associated with lower progression-free and overall survival in MM patients, independently of genetic alterations. These findings suggest that cancer-specific alternative active promoters could serve as new transcriptomic features for prognostic stratification in MM patients.
Article
Medicine, General & Internal
Philippe Moreau, Alfred L. Garfall, Niels W. C. J. van de Donk, Hareth Nahi, Jesus F. San-Miguel, Albert Oriol, Ajay K. Nooka, Thomas Martin, Laura Rosinol, Ajai Chari, Lionel Karlin, Lotfi Benboubker, Maria-Victoria Mateos, Nizar Bahlis, Rakesh Popat, Britta Besemer, Joaquin Martinez-Lopez, Surbhi Sidana, Michel Delforge, Lixia Pei, Danielle Trancucci, Raluca Verona, Suzette Girgis, Shun X. W. Lin, Yunsi Olyslager, Mindy Jaffe, Clarissa Uhlar, Tara Stephenson, Rian Van Rampelbergh, Arnob Banerjee, Jenna D. Goldberg, Rachel Kobos, Amrita Krishnan, Saad Z. Usmani
Summary: Teclistamab demonstrated promising efficacy in patients with relapsed or refractory multiple myeloma, leading to high rates of deep and durable response. Common adverse events included cytokine release syndrome, cytopenias, and infections, with toxic effects mostly grade 1 or 2.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Review
Oncology
Adam S. Sperling, Kenneth C. Anderson
Summary: One hallmark of cancer is the ability of tumor cells to evade and suppress the immune system, with multiple myeloma being a prime example. Decades of research have led to the discovery of various therapeutic agents, including those that alter immune interactions to combat myeloma. Progress in immunotherapy offers hope for a potential cure for this deadly disease.
CLINICAL CANCER RESEARCH
(2021)
Article
Multidisciplinary Sciences
Dongpeng Jiang, Haiwen Huang, Huimin Qin, Koukou Tang, Xiangru Shi, Tingting Zhu, Yuqing Gao, Ying Zhang, Xiaopeng Tian, Jianhong Fu, Weiwei Qu, Weilan Cai, Yang Xu, Depei Wu, Jianhong Chu
Summary: BCMA-targeting CAR-T therapy has shown promising responses in MM, but alternative targets are needed for BCMA-deficient tumors and BCMA antigen-loss relapse. This study reveals that FcRH5 is expressed on MM cells and can be targeted with CAR-T cells. FcRH5 CAR-T cells exhibit antigen-specific activation, cytokine secretion, and cytotoxicity against MM cells, and show robust tumoricidal efficacy in mouse models. FcRH5/BCMA-bispecific CAR-T cells demonstrate improved efficacy compared to mono-specific CAR-T cells.
NATURE COMMUNICATIONS
(2023)
Article
Oncology
Lijun Yao, Julia T. Wang, Reyka G. Jayasinghe, Julie O'Neal, Chia-Feng Tsai, Michael P. Rettig, Yizhe Song, Ruiyang Liu, Yanyan Zhao, Omar M. Ibrahim, Mark A. Fiala, Julie M. Fortier, Siqi Chen, Leah Gehrs, Fernanda Martins Rodrigues, Michael C. Wendl, Daniel Kohnen, Andrew Shinkle, Song Cao, Steven M. Foltz, Daniel Cui Zhou, Erik Storrs, Matthew A. Wyczalkowski, Smrithi Mani, Scott R. Goldsmith, Ying Zhu, Mark Hamilton, Tao Liu, Feng Chen, Ravi Vij, Li Ding, John F. DiPersio
Summary: This study utilizes single-cell transcriptomic profiling to identify potential therapeutic targets for multiple myeloma. The analysis identified 38 marker genes encoding cell-surface and intracellular proteins, including 11 previously uncharacterized targets. The findings provide valuable insights for the development of targeted antitumor therapy.
Article
Multidisciplinary Sciences
Na Zhao, Chunxia Qu, Yan Yang, Huihui Li, Yueyue Li, Hongbo Zhu, Zhiguo Long
Summary: This study revealed the correlation between dysregulated cholesterol metabolism and prognosis of multiple myeloma (MM). A prognostic signature was established and validated, showing good prognostic performance and correlation with clinical parameters. Functional and immune analysis indicated the association between metabolic pathways and immune status with risk score. The development and validation of this prognostic signature are expected to aid in predicting prognosis and guiding precision treatment for MM.
SCIENTIFIC REPORTS
(2023)
Article
Hematology
Taiga Nishihori, James E. Hoffman, Anne Huff, Gurpreet S. Kapoor, Ioanna Eleftheriadou, Stefan Zajic, Alisa Urbano, Sunil Suchindran, Michael Chisamore, Jimson W. D'Souza, Thomas Faitg, Aaron P. Rapoport
Summary: This pilot study evaluated the safety and efficacy of letetresgene autoleucel (lete-cel) alone or in combination with pembrolizumab in patients with relapsed/refractory multiple myeloma. The results showed transient antitumor activity and manageable safety profile of letetresgene autoleucel in these patients.
Editorial Material
Radiology, Nuclear Medicine & Medical Imaging
Dimitrios Strauss, Christos Sachpekidis, Ulrike Dapunt, Hartmut Goldschmidt, Antonia Dimitrakopoulou-Strauss
Summary: A 73-year-old man with multiple myeloma was found to have bilateral synchronous testicular manifestation during his F-18-FDG PET/CT scan. This rare finding was confirmed by histopathology after orchiectomy. Only a small percentage of multiple myeloma cases show testicular manifestation, and the optimal therapy management for such cases is still unclear.
CLINICAL NUCLEAR MEDICINE
(2023)
Article
Health Care Sciences & Services
Elina Alaterre, Veronika Vikova, Alboukadel Kassambara, Angelique Bruyer, Nicolas Robert, Guilhem Requirand, Caroline Bret, Charles Herbaux, Laure Vincent, Guillaume Cartron, Olivier Elemento, Jerome Moreaux
Summary: This study developed a gene risk score based on RNA-seq data for predicting the prognosis of newly diagnosed multiple myeloma patients treated with high-dose Melphalan and autologous stem cell transplantation. The risk score was associated with specific MM somatic mutation profiles and responses to targeted treatment, suggesting a potential utility for precision medicine strategies in MM.
JOURNAL OF PERSONALIZED MEDICINE
(2021)
Article
Immunology
Tiantian Ma, Jing Shi, Yuxia Xiao, Tianyue Bian, Jincheng Wang, Lingyun Hui, Mengchang Wang, Huasheng Liu
Summary: This study investigated the expression level of BCMA in the bone marrow of multiple myeloma patients and found correlations with disease stability, disease type, and certain prognostic factors, but not with age and serum creatinine levels.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Oncology
Julia Templin, Djordje Atanackovic, Daniel Hasche, Sabarinath Venniyil Radhakrishnan, Tim Luetkens
Review
Oncology
Djordje Atanackovic, Tim Luetkens
SEMINARS IN CANCER BIOLOGY
(2018)
Review
Immunology
Michael Olson, Sabarinath Venniyil Radhakrishnan, Tim Luetkens, Djordje Atanackovic
CLINICAL IMMUNOLOGY
(2019)
Letter
Oncology
Djordje Atanackovic, Sara Yousef, Christa Shorter, Srinivas K. Tantravahi, Mary Steinbach, Fiorella Iglesias, Douglas Sborov, Sabarinath Venniyil Radhakrishnan, Marielle Chiron, Rodney Miles, Mohamed Salama, Nicolaus Kroeger, Tim Luetkens
Review
Oncology
Peter G. Hendrickson, Michael Olson, Tim Luetkens, Siani Weston, Tiffany Han, Djordje Atanackovic, Gabriel C. Fine
Article
Multidisciplinary Sciences
Sabarinath V. Radhakrishnan, Tim Luetkens, Sandra D. Scherer, Patricia Davis, Erica R. Vander Mause, Michael L. Olson, Sara Yousef, Jens Panse, Yasmina Abdiche, K. David Li, Rodney R. Miles, William Matsui, Alana L. Welm, Djordje Atanackovic
NATURE COMMUNICATIONS
(2020)
Article
Hematology
Tim Luetkens, Ryan Metcalf, Vicente Planelles, Yue Zheng, Erin T. Larragoite, Emily S. Spivak, Adam M. Spivak, Mary Steinbach, Robert C. Blaylock, Stephanie Avila, Kim G. Hankey, Thomas B. Martins, Patricia R. Slev, Heather D. Mannuel, Mohammad Sajadi, Aaron P. Rapoport, Djordje Atanackovic
Review
Oncology
Erin Morales, Michael Olson, Fiorella Iglesias, Saurabh Dahiya, Tim Luetkens, Djordje Atanackovic
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2020)
Review
Immunology
Erin Morales, Michael Olson, Fiorella Iglesias, Tim Luetkens, Djordje Atanackovic
Summary: Ewing sarcoma is an aggressive cancer type that primarily affects teenagers, with limited success in immunotherapies possibly due to immunosuppressive factors in the tumor microenvironment. Efforts are being made to target these factors and improve the effectiveness of current and future immunotherapies for Ewing sarcoma patients.
Review
Biotechnology & Applied Microbiology
Erica R. Vander Mause, Djordje Atanackovic, Carol S. Lim, Tim Luetkens
Summary: The use of chimeric antigen receptor (CAR) T cells has revolutionized cancer treatment, however, the high affinity of most CAR-binding domains leads to excessive T-cell activation. Recent studies have explored the use of low-affinity CAR-binding domains and evaluated technologies to engineer and screen low-affinity antibody variants for CAR T-cell development, aiming to streamline the development of more functional and selective therapeutics.
TRENDS IN BIOTECHNOLOGY
(2022)
Letter
Oncology
Michael L. Olson, Erica R. Vander Mause, Sabarinath V. Radhakrishnan, Joshua D. Brody, Aaron P. Rapoport, Alana L. Welm, Djordje Atanackovic, Tim Luetkens
Editorial Material
Biotechnology & Applied Microbiology
Tim Luetkens
Article
Cell Biology
Erica R. Vander Mause, Jillian M. Baker, Kenneth A. Dietze, Sabarinath V. Radhakrishnan, Thierry Iraguha, Destiny Omili, Patricia Davis, Sadie L. Chidester, Katarzyna Modzelewska, Jens Panse, James E. Marvin, Michael L. Olson, Mary Steinbach, David P. Ng, Carol S. Lim, Djordje Atanackovic, Tim Luetkens
SCIENCE TRANSLATIONAL MEDICINE
(2023)
Review
Oncology
Djordje Atanackovic, Tim Luetkens, Sabari Radhakrishnan, Nicolaus Kroeger
CURRENT CANCER DRUG TARGETS
(2017)
Article
Oncology
Tim Luetkens, Sara Yousef, Sabarinath Venniyil Radhakrishnan, Djordje Atanackovic